COLONAID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COLONAID (COLONAID).
COLONAID acts as a selective 5-HT4 receptor agonist in the gastrointestinal tract, enhancing colonic motility and reducing visceral hypersensitivity. It also exhibits anti-inflammatory properties by inhibiting macrophage activation and cytokine release in colonic mucosa.
| Metabolism | Primarily metabolized by hepatic CYP3A4 to active metabolite N-desmethylcolonAid and further via CYP2D6. Minor renal excretion of unchanged drug (5%). |
| Excretion | Renal elimination of unchanged drug accounts for 70% of clearance; biliary/fecal elimination accounts for 25%; 5% is metabolized. |
| Half-life | Terminal elimination half-life is 18 hours (range 15–22 hours), supporting twice-daily dosing in patients with normal renal function. |
| Protein binding | 92% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8 L/kg (range 0.6–1.0 L/kg), indicating moderate distribution into total body water and some tissue binding. |
| Bioavailability | Oral: 65% (due to first-pass metabolism); intramuscular: 90%; subcutaneous: 85%. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate (within 5 minutes); intramuscular: 15–30 minutes. |
| Duration of Action | Oral: 6–8 hours; intravenous: 4–6 hours; intramuscular: 6–8 hours. Dose-dependent prolongation may occur at higher doses. |
COLONAID: 500 mg orally twice daily with meals.
| Dosage form | SOLUTION |
| Renal impairment | GFR 30-59 mL/min: 250 mg twice daily; GFR 15-29 mL/min: 250 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 250 mg twice daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Weight-based: 10 mg/kg orally twice daily; maximum 500 mg per dose. |
| Geriatric use | Initiate at 250 mg twice daily; increase to standard dose if tolerated. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COLONAID (COLONAID).
| Breastfeeding | Excreted into breast milk with M/P ratio of 0.8. Limited data in breastfeeding; use with caution due to potential adverse effects on infant's cardiovascular and renal function. Weigh benefits against risks. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show increased risk of skeletal malformations at supratherapeutic doses. Second trimester: Possible association with preterm labor due to prostaglandin inhibition. Third trimester: Risk of premature ductus arteriosus closure and oligohydramnios; avoid after 30 weeks gestation. |
■ FDA Black Box Warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR EVENTS. COLONAID may increase the risk of myocardial infarction, stroke, and arrhythmias due to its prokinetic effects on the heart. Use is contraindicated in patients with a history of cardiovascular disease, including prolonged QT interval, ischemic heart disease, or cerebrovascular accident.
| Serious Effects |
History of myocardial infarction, stroke, or transient ischemic attack; Prolonged QT interval (QTc >450 ms) or use of QT-prolonging drugs; Severe hepatic impairment (Child-Pugh C); Known hypersensitivity to 5-HT4 agonists
| Precautions | Monitor for cardiovascular events (ECG recommended before initiation); Avoid in patients with electrolyte disturbances; Use caution in hepatic impairment; May cause serotonin syndrome when used with other serotonergic drugs; Discontinue if signs of myocardial ischemia or arrhythmia develop. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, renal function, and amniotic fluid volume weekly. Fetal echocardiography for ductal flow if used after 20 weeks. Surveillance for preterm contractions. |
| Fertility Effects | May impair ovulation via luteal phase suppression. Reversible upon discontinuation. No known effect on spermatogenesis. |